Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Bought by Nomura Asset Management Co. Ltd.

Nomura Asset Management Co. Ltd. raised its position in Structure Therapeutics Inc. (NASDAQ:GPCR) by 25.5% during the fourth quarter, HoldingsChannel reports. The firm owned 36,925 shares of the company’s stock after buying an additional 7,496 shares during the quarter. Nomura Asset Management Co. Ltd.’s holdings in Structure Therapeutics were worth $1,001,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. ANTIPODES PARTNERS Ltd raised its stake in Structure Therapeutics by 115.0% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company’s stock valued at $28,000 after buying an additional 553 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Structure Therapeutics by 4,155.6% in the 4th quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock valued at $31,000 after acquiring an additional 1,122 shares during the last quarter. FNY Investment Advisers LLC acquired a new stake in shares of Structure Therapeutics during the 4th quarter worth about $40,000. Assetmark Inc. lifted its stake in Structure Therapeutics by 72.3% during the fourth quarter. Assetmark Inc. now owns 2,271 shares of the company’s stock worth $62,000 after purchasing an additional 953 shares during the last quarter. Finally, Jones Financial Companies Lllp boosted its holdings in Structure Therapeutics by 29.8% in the fourth quarter. Jones Financial Companies Lllp now owns 4,228 shares of the company’s stock valued at $115,000 after purchasing an additional 971 shares in the last quarter. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Stock Performance

NASDAQ GPCR opened at $16.95 on Thursday. Structure Therapeutics Inc. has a one year low of $15.31 and a one year high of $62.74. The firm has a market cap of $971.96 million, a PE ratio of -22.91 and a beta of -2.37. The firm’s fifty day moving average is $23.52 and its two-hundred day moving average is $30.73.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.01. Research analysts predict that Structure Therapeutics Inc. will post -0.82 earnings per share for the current year.

Wall Street Analyst Weigh In

GPCR has been the topic of a number of research analyst reports. Stifel Nicolaus initiated coverage on shares of Structure Therapeutics in a report on Wednesday, January 8th. They set a “buy” rating and a $50.00 price objective on the stock. JMP Securities reiterated a “market outperform” rating and set a $91.00 price target on shares of Structure Therapeutics in a research note on Wednesday, December 18th. William Blair initiated coverage on shares of Structure Therapeutics in a research note on Friday, February 28th. They issued an “outperform” rating for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $80.00 price objective on shares of Structure Therapeutics in a report on Thursday, December 19th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Structure Therapeutics presently has an average rating of “Buy” and a consensus price target of $81.29.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.